Tuberculosis
We focus our work on the detection, treatment, prevention and research of tuberculosis (TB) and its multiple variants, with a social approach and through research and development of new technologies.
.
OUR IMPACT
Over the past year, we strengthened health services to improve access and care for those affected by TB, MDR-TB and XDR-TB.
.
28 862peoplescreened for tuberculosis, 87% through active search strategies
.
1428peopledetected with the disease could be referred to the health system to begin treatment
.
25 000radiographscarried out in health campaigns throughout Metropolitan Lima and Trujillo for the diagnosis of suspected TB
.
The value of our work
En 1996, Socios En Salud (SES) inicia la administración del primer grupo de pacientes con tuberculosis multidrogoresistente (TB MDR), bajo un modelo DOTS basado en la comunidad (Terapia de Observación Directa).
SES successfully cured 75 MDR-TB patients, with a cure rate of over 85%, surpassing cure rates in the U.S. This success inspired the WHO to revise treatment protocols, showing the possibility of treating the disease in disadvantaged settings and leading to changes in global recommendations.
En el 2000, SES expande el programa de tratamiento de TB-MDR a los distritos con mayor carga de TB de Lima y Callao a través de un financiamiento de la Fundación Bill & Melinda Gates.
At age 32, Yunaidy was diagnosed with tuberculosis and received medical treatment, community follow-up, mental health care and socioeconomic support for six months from SES. Thanks to this comprehensive intervention, she was able to overcome TB.
.
In 2017, SES becomes a Principal Recipient of the Global Fund TB project, focused on serving priority groups and strengthening the community system, addressing prisons, resistant TB and TB-HIV.
A través del proyecto TB Móvil, SES recibió el reconocimiento “Perú por los Objetivos de Desarrollo Sostenible” Edición 2022, en la categoría Personas, subcategoría ONG.
.
